DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

February 15, 2023

DISEASE EDUCATION & CALLING ALL HEALTH AND INCREASED PATIENT ACCESS INVESTORS

This Month, I’d like to introduce you to the company, Reglagene, www.reglagene.com, a therapeutics company located in Tucson, AZ transforming tubulin targeting therapy for CNS diseases.  Their pipeline also includes disease indications driven by brain inflammation.  My personal ask is if you are an investor in healthcare with a desire to support and advance patient access to treatments because patients deserve better therapies that improve Quality of Life (QOL) as well as extend life, please contact directly Co-founder & CEO, Richard Austin at info@reglagene.com,  #RichardAustin, #Reglagene.  Reglagene is also seeking a Chief Medical Officer to move their GBM molecule into human clinical trials.  Please send resume to Richard at the above email address if you are interested in learning more.

Reglagene’s lead program is a novel, orally administered, first-in-class well tolerated, blood brain barrier (BBB) penetrant therapy for the treatment of brain cancers including GBM and metastasized disease to the brain. To learn more, go to www.EndBrainCancer.org and type in the search bar “Reglagene”. There also an informative Reglagene video available on the web.

THANK YOU for your support to increase Patient ACCESS!!!

Photo of Dellann

Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org

EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram